COSMIC-021 Phase I Study: Cabozantinib Plus Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in androgen deprivation therapy for prostate cancer

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: October 6, 2021 Expired: October 5, 2022

Health-related quality of life, pain, safety outcomes from VISION trial of 177Lu-PSMA-617 in men with mCRPC presented at the 2021 ESMO Congress, reported by Clinical Care Options (CCO)